Skip to Content

Notice

Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN; Correction

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of March 21, 2011 (76 FR 15323). The document announced the determination of the regulatory review period for ATRYN. The document was published with an incorrect docket number. This document corrects that error.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Joyce Strong, Office of Policy, Planning and Budget, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3208, Silver Spring, MD 20993-0002, 301-796-9138.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In FR Doc. 2011-6509, appearing on page 15323, in the Federal Register of Monday, March 21, 2011, the following correction is made:

1. On page 15323, in the first column, in the Docket No. heading, “[Docket No. FDA-2010-E-0241]” is corrected to read “[Docket No. FDA-2009-E-0241]”.

Start Signature

Dated: April 8, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2011-9153 Filed 4-14-11; 8:45 am]

BILLING CODE 4160-01-P